Clinical Trial Update: A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CTA30X cell injection in relapsed or refractory CD19-positive B-line hematological malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CTA30X cell injection

Snippet

Sponsor: He Huang | Conditions: Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | EARLY_Phase 1 | Status: COMPLETED